Long‐term treatment of swiss 3T3 fibroblasts with dexamethasone attenuates MAP kinase activation induced by insulin‐like growth factor‐I (IGF‐I)
Authors:
- 1 June 1996
- journal article
- research article
- Published by Wiley in Cell Biochemistry and Function
- Vol. 14 (2) , 121-129
Abstract
Bone formation is reduced in hyperglucocorticoid states, e.g. Cushing's syndrome or long‐term treatment with synthetic glucocorticoids during rheumatic diseases. Possibly related to decreased sensitivity of the target to insulin‐like growth factor‐I (IGF‐I). In this study, we have sought to identify postreceptor‐mechanisms for glucocorticoid‐induced resistance to insulin‐like peptides in a model system. Treatment of Swiss 3T3 fibroblasts with 100 nM dexamethasone for 48 h reduced IGF‐I‐induced activation of mitogen‐activated protein kinase (MAP kinase). The level of insulin receptor substrate‐1 (IRS‐1) was reduced in dexamethasone‐treated cells, as measured by Western blot; however, the pattern of tyrosine‐phosphorylated protein subsequent to stimulation with IGF‐I (1 min) was not altered. No inhibitory effect of dexamethasone was observed on the level of phosphotyrosine in IRS‐1 in extracts from IGF‐I‐treated cells. The amount of IGF‐I‐induced association of insulin receptor substrate‐1 and phosphatidylinositol 3‐kinase was increased in steroid treated cells. Addition of IGF‐I increased the synthesis of lipid, glycogen and protein, and the reduction of a tetrazolium dye, MTS, in untreated cells. The response to IGF‐I in terms of glycogen synthesis was blunted, whereas the effect of IGF‐I was unaffected for the other three parameters in cells pretreated with dexamethasone. These findings indicate that the activation of MAP kinase may be dissociated from IGF‐I‐induced anabolic pathways and tyrosine phosphorylationof IRS‐1. The results agree with the previously proposed role for the activation of MAP kinase in the regulation of glycogen synthesis. Furthermore, they suggest that dexamethasone‐induced reduction of IRS‐1 expression may be important for the impaired activation of MAP kinase by insulin‐like peptides in steroid‐treated cells.Keywords
Funding Information
- Magnus Bergvalls FoundationNovo Nordisk Foundation
This publication has 51 references indexed in Scilit:
- Inactivation of Glycogen Synthase Kinase-3 by Epidermal Growth Factor Is Mediated by Mitogen-activated Protein Kinase/p90 Ribosomal Protein S6 Kinase Signaling Pathway in NIH/3T3 CellsJournal of Biological Chemistry, 1995
- Skeletal unloading induces resistance to insulin-like growth factor IJournal of Bone and Mineral Research, 1994
- Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors.Genes & Development, 1994
- Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo.Journal of Clinical Investigation, 1993
- The MAP kinase cascade is essential for diverse signal transduction pathwaysTrends in Biochemical Sciences, 1993
- Protein kinase C-dependent activation of a myelin basic protein kinase by gastrin-releasing peptide in Swiss 3T3 fibroblastsCellular Signalling, 1991
- Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6)Progress in Growth Factor Research, 1991
- The somatomedin-insulin-like growth factorsJournal of Internal Medicine, 1989
- Insulin-induced tyrosine-phosphorylation in intact rat adipocytesBiochemical and Biophysical Research Communications, 1988
- Regulation of Bone FormationNew England Journal of Medicine, 1983